Clinical Trial

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Name: Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes — clinical trial record (NCT07187752)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This study will evaluate the safety and efficacy of neoadjuvant trastuzumab, pertuzumab and chemotherapy chosen by the investigators and identify the molecular characterization and subtypes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Trial Details

NCT Number	NCT07187752
Lead Sponsor	Shandong Cancer Hospital and Institute
Conditions	Breast Cancer
Enrollment	1,039 participants
Start Date	2025-09-30
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-23